menu
    • menu
    [{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"SEARCHLIGHT PHARMA","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"SEARCHLIGHT PHARMA \/ SEARCHLIGHT PHARMA","highestDevelopmentStatusID":"10","companyTruncated":"SEARCHLIGHT PHARMA \/ SEARCHLIGHT PHARMA"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"SEARCHLIGHT PHARMA","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"SEARCHLIGHT PHARMA \/ SEARCHLIGHT PHARMA","highestDevelopmentStatusID":"10","companyTruncated":"SEARCHLIGHT PHARMA \/ SEARCHLIGHT PHARMA"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SEARCHLIGHT PHARMA","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"SEARCHLIGHT PHARMA \/ SEARCHLIGHT PHARMA","highestDevelopmentStatusID":"15","companyTruncated":"SEARCHLIGHT PHARMA \/ SEARCHLIGHT PHARMA"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SEARCHLIGHT PHARMA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"SEARCHLIGHT PHARMA \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"SEARCHLIGHT PHARMA \/ Apotex Inc"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Apotex Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"||Retinoic acid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SEARCHLIGHT PHARMA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"SEARCHLIGHT PHARMA \/ Apotex Inc","highestDevelopmentStatusID":"15","companyTruncated":"SEARCHLIGHT PHARMA \/ Apotex Inc"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"JAPAN","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Linzagolix","moa":"GnRH receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"SEARCHLIGHT PHARMA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"SEARCHLIGHT PHARMA \/ Searchlight Pharma","highestDevelopmentStatusID":"15","companyTruncated":"SEARCHLIGHT PHARMA \/ Searchlight Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by SEARCHLIGHT PHARMA

    Menu

    SEARCHLIGHT PHARMA

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SEARCHLIGHT PHARMA

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SEARCHLIGHT PHARMA

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Linzagolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Recipient : Kissei Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Apotex Strengthens Commitment to Women's Health with Canadian Rights to Linzagolix

                            Details : Through the licensing deal for Linzagolix, targeting the GnRH receptor, the agreement aims to advance treatment options for uterine fibroids.

                            Product Name : Yselty

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 07, 2025

                            Lead Product(s) : Linzagolix

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Recipient : Kissei Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SEARCHLIGHT PHARMA

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SEARCHLIGHT PHARMA

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Apotex Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Apotex Acquires Searchlight, a Canadian Specialty Innovative Branded Pharma Company

                            Details : Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist in combination with Benzoyl Peroxide indicated for the topical treatment of acne vulgaris.

                            Product Name : Twyneo

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 03, 2024

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Apotex Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SEARCHLIGHT PHARMA

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SEARCHLIGHT PHARMA

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Apotex Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader

                            Details : Through acquisition, Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist combined with Benzoyl Peroxide for treating acne vulgaris in patients aged 9 and older.

                            Product Name : Twyneo

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 02, 2024

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Apotex Inc

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SEARCHLIGHT PHARMA

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SEARCHLIGHT PHARMA

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Estetrol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Recipient : Mithra Pharmaceuticals

                            Deal Size : $17.9 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mithra and Searchlight Pharma Sign DONESTA® Licensing Agreement for Canada

                            Details : Under the terms of the agreement, Searchlight will have sales and marketing rights for DONESTA® in Canada. DONESTA (estetrol) phase 3 clinical program, which demonstrated a meaningful reduction in the frequency and severity of vasomotor symptoms compare...

                            Product Name : Donesta

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 26, 2023

                            Lead Product(s) : Estetrol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Recipient : Mithra Pharmaceuticals

                            Deal Size : $17.9 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SEARCHLIGHT PHARMA

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SEARCHLIGHT PHARMA

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Estetrol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Recipient : Mithra Pharmaceuticals

                            Deal Size : $18.7 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Mithra and Searchlight Pharma Announce Donesta® Licensing Agreement for Canada

                            Details : Under the agreement, Searchlight will have the Canadian rights to Donesta, a next generation orally administered Estetrol (E4)-based hormone therapy product, for the treatment of the symptoms of menopause.

                            Product Name : Donesta

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 31, 2023

                            Lead Product(s) : Estetrol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Recipient : Mithra Pharmaceuticals

                            Deal Size : $18.7 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SEARCHLIGHT PHARMA

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            SEARCHLIGHT PHARMA

                            Canada arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Recipient : Sol-Gel Technologies

                            Deal Size : $11.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

                            Details : Under the agreement, Searchlight Pharma will be responsible for obtaining and maintaining any regulatory approvals required to market and sell Twyneo (tretinoin), used for acne vulgaris and Epsolay (benzoyl peroxide), used for inflammatory lesions of ros...

                            Product Name : Twyneo

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 06, 2023

                            Lead Product(s) : Tretinoin,Benzoyl Peroxide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Recipient : Sol-Gel Technologies

                            Deal Size : $11.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth